{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"67.64","upperLimit":"82.32","value":"75.5"},{"groupId":"OG001","lowerLimit":"75.01","upperLimit":"88.02","value":"82.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"description":"To evaluate the efficacy of TORIPALIMAB INJECTION(JS001) plus chemotherapy compared with placebo plus chemotherapy, as measured by investigator-assessed overall response rate (ORR) according to RECIST v1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Gemcitabine 1000 mg/m² IV are given on Days 1 \\& 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，placebo will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and placebo for up to 2 years","id":"OG000","title":"Placebo Combine With Chemotherapy"},{"description":"Gemcitabine 1000 mg/m² IV are given on Days 1 \\& 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，JS001 will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and JS001 for up to2years","id":"OG001","title":"TORIPALIMAB INJECTION(JS001 )Combine With Chemotherapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From date of randomization, until disease progression , loss of clinical benefit ,withdrawal of consent, death, or study termination by the Sponsor, whichever occurs first. Up to 2 approximately years","title":"Investigator-assessed ORR According to RECIST v1.1","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}